EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group

This publication has 11 references indexed in Scilit:

• DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?
  British Journal of Cancer, 1995
• Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase
  British Journal of Cancer, 1995
• Phase I and Pharmacologic Study of the Novel Indoloquinone Bioreductive Alkylating Cytotoxic Drug E09
  JNCI Journal of the National Cancer Institute, 1994
• Cyclopropamitosenes
  Anti-Cancer Drugs, 1994
• Relative importance of DT-diaphorase and hypoxia in the bioactivation of e09 by human lung tumor cell lines
  International Journal of Radiation Oncology*Biology*Physics, 1994
• Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression
  Biochemical Pharmacology, 1994
• Unusually marked hypoxic sensitization to indoloquinone E09 and mitomycin C in a human colon‐tumour cell line that lacks DT‐diaphorase activity
  International Journal of Cancer, 1994
• EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models
  European Journal Of Cancer, 1993
• In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity
  British Journal of Cancer, 1992
• Mitomycin analogs I. Indoloquinones as (potential) bisalkylating agents
  Tetrahedron, 1987